ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1147

Definition of Improvement Thresholds in Juvenile Idiopathic Arthritis Using the JADAS

Gerd Horneff1 and Ingrid Kaul2, 1Department of Pediatrics, Centre of Pediatric Rheumatology, Sankt Augustin, Germany, 2Institute of Medical Statistics, Informatics and Epidemiology, University of Cologne, Cologne, Germany

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: etanercept, juvenile arthritis and methotrexate (MTX)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis

Session Type: Abstract Submissions (ACR)

Definition of improvement thresholds in juvenile idiopathic arthritis (JIA) using the JADAS

 

Background/Purpose: Evaluation of disease activity in JIA is fundamental in clinical assessment. The ACR paediatric response measure used in clinical trials are validated to analyse the response to a treatment in comparison to a baseline disease activity but does not judge about the absolute disease activity or the absolute improvement.

Methods: The JADAS has been calculated in patients of the BIKER registry newly starting treatment with etanercept or MTX. The JADAS10 was preferred because it values all 4 domains equally. Physicians + parents were requested to judge on treatment efficacy as very good, good, weak, none or worse. Improvement was assumed if judgement of both were very good or good. No improvement was assumed if at least one judgement was for none or poor. Inconclusive judgements or those with a difference >1 point were excluded from analysis.

Results: Initially, ANOVA of JIA categories showed no significant differences of mean DJADAS in all baseline classes and IQRs also showed good overall limits. So, all JIA categories were combined for a joint cutoff. Analysis was restricted to the 3 month evaluation because of a time dependence of the judgement of improvement in terms of the JADAS. Restriction to the 3 month results left 1340 patients. JADAS at baseline was finally put into 4 classes, class 0 for JADAS <5, “low” for 5≤JADAS<15, “moderate” for 15 ≤JADAS<25 and ”high” for 25≤JADAS≤40. An initial JADAS of <5 was assumed as only minor or no disease activity. An improvement cutoff was only defined for baseline classes “low”, “moderate” and “high”. Cutoffs for defining improvement were chosen by calculating interquartile ranges (IQR) of the judgement groups and considering accuracy as well as sensitivity/specificity of the resulting model. Analysis by baseline class revealed clear cutoff points. According to the baseline JADAS class the following minimum decreases of the JADAS (DJADAS) are proposed for definition of improvement: For baseline class ”low”: DJADAS of 4, for baseline class ”moderate”:  DJADAS of 10, for baseline class ”high”:  DJADAS of 15. Alternatively a relative decrease of the JADAS by 42% for JADAS class “low”, by 51% for JADAS Class ”moderate” and 56% for JADAS class ”high” were found to define improvement. (table1)

Conclusion: Disease improvement on therapy can efficiently be defined by the decrease of the JADAS depending on the initial JADAS score defining low, moderate or high disease activity. Our model demonstrates clear cut off values. After cross validation these cutoffs may be used in clinical trials and for decisions in clinical practice.

 

Table 1: Inter quartile ranges of variable DJADAS10 by improvement and baseline class, absolute and relative values. Chosen cutoff for improvement and goodness-of-fit parameters. Higher DJADAS10 indicate better treatment efficacy. Only integer cutoffs were considered.

 

 

JADAS10 baseline class

 

Low

(5-15)

Moderate

(15-25)

High

(25-40)

Improvement

DJadas10 absolute values IQR (n)

Yes

4.1–9.5 (502)

10.4-17.2 (450)

17.8-27.2 (148)

No

-31. – 3.7 (85)

1.5-10.2 (94)

4.6-15.0 (35)

Cutoff for improvement

4

10

15

Accuracy [%]

76.2

74.8

85.8

Sensitivity

75.9

76.2

88.5

Specificity

76.5

73.4

74.3

Improvement

DJadas10 relative values [%] IQR

Yes

45 – 86

55 – 88

65 – 94

No

-32 – 42

8- 50

18 – 49

Cutoff for improvement

42

51

50

53

56

Accuracy [%]

76.8

78.5

88.0

87.4

87.4

Sensitivity

77.1

78.4

90.5

88.5

87.2

Specificity

75.3

78.7

77.1

82.9

88.6

 


Disclosure:

G. Horneff,
None;

I. Kaul,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/definition-of-improvement-thresholds-in-juvenile-idiopathic-arthritis-using-the-jadas/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology